Skip to main content
SpringerLink
Log in

Effect of an Educational Program (PEGASE) on Cardiovascular Risk in Hypercholesterolaemic Patients

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Background

Many studies have demonstrated a gap between guidelines for the prevention of cardiovascular disease (CVD) and their implementation in clinical practice.

Aim

The PEGASE education program has been devised with an aim to improve the management of patients at high risk of CVD.

Methods

In a multicentre study carried out from 2001–2004 in France, 96 participating physicians were randomized into a “trained” group, which included 398 “educated” patients, and a “non-trained” group, which included 242 “non-educated” patients. Educated patients received six hospital-based educational sessions, four collective and two individual. Framingham score, smoking, lipid levels, glycaemia, blood pressure, dietary intake and drug compliance, as well as quality of life, were evaluated at baseline (M0) and 6 months (M6). The primary endpoint of the study was the efficacy of the PEGASE program in reducing global CVD risk in high-risk patients.

Results

The Framingham score was calculated for 473 patients. The Framingham score improved significantly at M6 vs M0 in the educated group (13.0 ± 8.21 vs 13.6 ± 8.48, d = −0.658, p = 0.016), but not in the non-educated group (12.5 ± 8.19 vs 12.4 ± 7.81, d = +0.064, p = 0.836); the mean change between the two groups did not reach significance. Quality of life, LDL-c level and diet scores improved in the “educated” group only.

Conclusions

The PEGASE education program improved risk factors for CVD, although global assessment by Framingham score was not significantly different between groups. This program, aimed at meeting needs and expectations of patients and physicians, was easily implemented in all hospital centres.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Murray CJL, Lopez AD (eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health; 1996

  2. World Health Organization cardiovascular disease fact sheet [online]. URL: http://www.who.int/cardiovascular_diseases/en/. Accessed 19 December 2007.

  3. Forrester JS, Merz CN, Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 4. Efficacy of risk factor management. J Am Coll Cardiol 1996;27:991–1006.

    Article  PubMed  CAS  Google Scholar 

  4. Kita T. Coronary heart disease risk in Japan—an East/West divide. Eur Heart J. 2004;6:A8–11.

    Google Scholar 

  5. Gupta R, Sarna M, Thanvi J, Rastogi P, Kaul V, Gupta VP. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3. Indian Heart J. 2004;56:646–52.

    PubMed  Google Scholar 

  6. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9.

    Article  Google Scholar 

  7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–7.

    Article  PubMed  CAS  Google Scholar 

  8. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.

    Article  PubMed  Google Scholar 

  9. EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997;18:1569–82. Erratum in: Eur Heart J 1998; 19:356–357.

    Google Scholar 

  10. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J. 2001;22:554–72.

    Article  Google Scholar 

  11. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol. 1995;76:570–3.

    Article  Google Scholar 

  12. Ellerbeck EF, Jencks SF, Radford MJ, Kresowik TF, Craig AS, Gold JA, et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA. 1995;273:1509–14.

    Article  PubMed  CAS  Google Scholar 

  13. McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med. 1996;156:799–805. Erratum in: Arch Intern Med 1996; 156:1920.

    Article  PubMed  CAS  Google Scholar 

  14. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation. 1998;98:851–5.

    PubMed  CAS  Google Scholar 

  15. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 2001;357:995–1001.

    Article  Google Scholar 

  16. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303–7. Erratum in: Am J Cardiol 1999; 84:1143.

    Article  PubMed  CAS  Google Scholar 

  17. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106–8.

    Article  PubMed  Google Scholar 

  18. House WC, Pendleton L, Parker L. Patients’ versus physicians’ attributions of reasons for diabetic patients’ noncompliance with diet. Diabetes Care. 1986;9:434.

    PubMed  CAS  Google Scholar 

  19. Riesen WF, Darioli R, Noll G. Lipid-lowering therapy: strategies for improving compliance. Curr Med Res Opin. 2004;20:165–73.

    Article  PubMed  Google Scholar 

  20. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European Society of Cardiology Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1–10.

    Article  PubMed  Google Scholar 

  21. Pearson TA, McBride PE, Miller NH, Smith SC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol. 1996;27:1039–47.

    Article  PubMed  CAS  Google Scholar 

  22. Revell CC, Schroeder SA. Simplicity matters: using system-level changes to encourage clinician intervention in helping tobacco users quit. Nicotine Tob Res. 2005;7(Suppl 1):S67–9.

    Article  PubMed  Google Scholar 

  23. Ebrahim S, Davey Smith G. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ. 1997;314:1666–74.

    PubMed  CAS  Google Scholar 

  24. Ferrieres J, Durack-Bown I, Giral P, Chadarevian R, Benkritly A, Bruckert E. Patient education and patient at risk. A new approach in cardiology. Ann Cardiol Angeiol (Paris). 2006;55:27–31.

    Article  CAS  Google Scholar 

  25. Prochaska JO, Di Clemente CC. Stages of change in the modification of problem behaviors. Prog Behav Modif. 1992;28:183–218.

    PubMed  CAS  Google Scholar 

  26. WHO Working Group Report. Therapeutic Patient Education: Continuing education programmes for healthcare providers in the field of prevention of chronic diseases. Copenhagen, Denmark: WHO-Europe; 1998.

    Google Scholar 

  27. Durack-Bown I, Giral I, d’Ivernois JF, Bazin C, Chadarevian R, Benkritly A, et al. Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract. 2003;53:851–7.

    PubMed  Google Scholar 

  28. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160–4.

    PubMed  CAS  Google Scholar 

  29. Norman A, Bellocco R, Bergstrom A, Wolk A. Validity and reproducibility of self-reported total physical activity—differences by relative weight. Int J Obes Relat Metab Disord. 2001;25:682–8.

    Article  PubMed  CAS  Google Scholar 

  30. Laviolle B, Froger-Bompas C, Guilloc P, Sevestred A, Letelliere C, Pouchard M, et al. Relative validity and reproducibility of a 14-item semi-quantitative food frequency questionnaire for cardiovascular prevention. Eur J Cardiovasc Prev Rehabil. 2005;12:587–95.

    Article  PubMed  Google Scholar 

  31. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991;83:357–63.

    Google Scholar 

  32. Nguyen Phong Chau LD, Cazelles B, Segond P, PCV-Metra Group. Estimation of CHD risk in a French working population using a modified Framingham model.. J Clin Epidemiol. 1994;47:1353–64.

    Article  Google Scholar 

  33. Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002;31:817–22.

    Article  PubMed  Google Scholar 

  34. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group 2001. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–7.

    Article  PubMed  Google Scholar 

  35. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267.

    Article  PubMed  Google Scholar 

  36. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J. 2003;24:1903–11.

    Article  PubMed  CAS  Google Scholar 

  37. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, et al. Legume consumption and risk of coronary heart disease in US men and women. NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:2573–8.

    Article  PubMed  CAS  Google Scholar 

  38. Ellingsen I, Hjermann I, Abdelnoor M, Hjerkinn EM, Tonstad S. Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study. Am J Clin Nutr. 2003;78:935–40.

    PubMed  CAS  Google Scholar 

  39. Lichtman JH, Amatruda J, Yaari S, Cheng S, Smith GL, Mattera JA, et al. Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. Am Heart J. 2004;147:522–8.

    Article  PubMed  Google Scholar 

  40. Sartorio A, Lafortuna CL, Marinone PG, Tavani A, La Vecchia C, Bosetti C. Short-term effects of two integrated, non-pharmacological body weight reduction programs on coronary heart disease risk factors in young obese patients. Diabetes Nutr Metab. 2003;16:262–5.

    PubMed  CAS  Google Scholar 

  41. Burke LE, Dunbar-Jacob J, Sereika S, Ewart CK. Development and testing of the Cholesterol-Lowering Diet Self-Efficacy Scale. Eur J Cardiovasc Nurs. 2003;2:265–73.

    Article  PubMed  Google Scholar 

  42. Mullen PD, Mains DA, Velez RA. Meta-Analysis of controlled trials of Cardiac Patient Education. Patient Educ Couns. 1992;19:143–62.

    Article  PubMed  CAS  Google Scholar 

  43. Mehta RH, Montoye CK, Gallogly M, Baker P, Blount A, Faul J, et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA. 2002;287:1269–76.

    Article  PubMed  Google Scholar 

  44. Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 2000;85:10A–7A.

    Article  PubMed  CAS  Google Scholar 

  45. Tsuyuki RT, Johnson JA, Teo KK, Ackman ML, Biggs RS, Cave A, et al. Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother. 1999;33:910–9.

    Article  PubMed  CAS  Google Scholar 

  46. Reid V, Barnes E, Daly L. Information sessions for outpatients referred to a hospital Nutrition and Dietetic Service for cholesterol lowering advice. J Hum Nutr Diet. 2001;15:281–6.

    Article  Google Scholar 

  47. Ammerman AS, Keyserling TC, Atwood JR, Hosking JD, Zayed H, Krasny C. A randomized controlled trial of a public health nurse directed treatment program for rural patients with high blood cholesterol. Prev Med. 2003;36:340–51.

    Article  PubMed  Google Scholar 

  48. Robinson JG, Conroy C, Wickemeyer WJ. A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol ≤100 mg/dl. Am J Cardiol. 2000;85:305–8.

    Article  PubMed  CAS  Google Scholar 

  49. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: results of the first myocardial infarction risk reduction program. Clin Ther. 2001;23:970–80.

    Article  PubMed  CAS  Google Scholar 

  50. Soignantes E. Photolanguage, a group psychotherapy. Soins Psychiatr. 1998;196:16–20.

    PubMed  Google Scholar 

  51. Baptiste A, Belisle C. Photolangage®. Prévention et Santé (dossier: 48 photos). Paris: Les éditions d’Organisation; 1994. p. 91–122.

    Google Scholar 

  52. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367–73.

    Article  Google Scholar 

  53. Simon JA, Carmody TP, Hudes ES, Snyder E, Murray J, Simon JA, et al. Intensive smoking cessation counseling versus minimal counseling among hospitalized smokers treated with transdermal nicotine replacement: a randomized trial. Am J Med. 2003;114:555–62.

    Article  PubMed  Google Scholar 

  54. Ranney L, Melvin C, Lux L, McClain E, Lohr KN. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145:845–56.

    PubMed  Google Scholar 

  55. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE, et al. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. Chest. 2007;131:446–52.

    Article  PubMed  Google Scholar 

  56. Sohn M, Stotts NA, Benowitz N, Christopherson D, Kim KS, Jang YS, et al. Beliefs about health, smoking, and future smoking cessation among South Korean men hospitalized for cardiovascular disease. Heart Lung. 2007;36:339–47.

    Article  PubMed  Google Scholar 

  57. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. JAMA. 1990;263:1795–801. Erratum in: JAMA 1990; 263:3151.

    Article  Google Scholar 

  58. O’Malley PG, Kowalczyk C, Bindeman J, Taylor AJ. The impact of cardiovascular risk factor case management on the metabolic syndrome in a primary prevention population: results from a randomized controlled trial. J Cardiometab Syndr. 2006;1:6–12.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

English language assistance for the preparation of this manuscript was provided by Sheridan Henness. This assistance was funded by AstraZeneca France.

Author information

Authors and Affiliations

  1. Groupe hospitalier Pitié-Salpétrière, Service d’Endocrinologie-Métabolisme, 47-83, Boulevard de l’Hôpital, 75651, Paris Cedex 13, France

    Eric Bruckert & Philippe Giral

  2. CHU, Rennes, France

    François Paillard

  3. CHU, Toulouse, France

    Jean Ferrières

  4. CHU, Strasbourg, France

    Jean-Louis Schlienger

  5. CHU, Marseille, France

    Jean-François Renucci

  6. CCN, Saint-Denis, France

    Kamel Abdennbi

  7. Edusanté, Paris, France

    Isabelle Durack

  8. AstraZeneca, Paris, France

    Rita Chadarevian

Authors
  1. Eric Bruckert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Giral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. François Paillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Ferrières
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Louis Schlienger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-François Renucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kamel Abdennbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Isabelle Durack
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rita Chadarevian
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

PEGASE group

Corresponding author

Correspondence to Eric Bruckert.

Additional information

The study and the PEGASE educational program were supported by AstraZeneca France.

E. Bruckert has received speaker’s fees from Astra Zeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruckert, E., Giral, P., Paillard, F. et al. Effect of an Educational Program (PEGASE) on Cardiovascular Risk in Hypercholesterolaemic Patients. Cardiovasc Drugs Ther 22, 495–505 (2008). https://doi.org/10.1007/s10557-008-6137-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-008-6137-4

Key words

Search

Navigation